Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorprothixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorprothixene SCHEMBL30383335 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL94235 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29626798 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL94236 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29357955 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL455759 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29857011 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL455758 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL3491182 | 0.92 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29462906 | 0.90 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1918 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY INC (US) | 2025-05-15 | — | — | US | claimed |
| EP-4472637-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | Kura Oncology, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| WO-2023150635-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20220050117-A1 | GLX-DERIVED MOLECULE DETECTION | GLX ANALYTIX APS (DK) | 2022-02-17 | — | — | US | claimed |
| CN-108593828-A | Blood plasma prepares the detection method of drug and toxic content in card | 李水军 | 2018-09-28 | — | — | CN | claimed |
| CN-107088191-A | The new application of medicine taractan | 深圳市坤健创新药物研究院 | 2017-08-25 | — | — | CN | claimed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| CN-104965035-B | Method for screening toxic substances in sample by using solid phase support liquid-liquid extraction-GC MS | 公安部物证鉴定中心 | 2017-02-01 | — | — | CN | claimed |
| CN-104965035-A | Method for screening toxic substances in sample by using solid phase support liquid-liquid extraction-GC MS | INST FORENSIC SCIENCE MINISTRY PUBLIC SECURITY PRC | 2015-10-07 | — | — | CN | claimed |
| JP-2000516204-A | — | — | 2000-12-05 | — | — | JP | claimed |
| EP-0954327-A1 | USEFUL FORMULATIONS OF ACID ADDITION SALT DRUGS | OXIGENE, INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1999025353-A1 | THERAPEUTIC USES OF TRIAZOLO-PYRIDAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-05-27 | — | — | WO | claimed |
| WO-1998000159-A1 | USEFUL FORMULATIONS OF ACID ADDITION SALT DRUGS | OXIGENE, INC. (US) | 1998-01-08 | — | — | WO | claimed |
| WO-1994023726-A1 | CALMODULIN BLOCKING AGENT ADDUCTS USEFUL AS ANTI-PLATELET AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| CN-1093934-A | Protective sheath for pasting and moxibustion | CHEN JIE (CN) | 1994-10-26 | — | — | CN | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| EP-0126848-B1 | SUSPENSION AGENT MIXTURE AS AN ADDITIVE TO CALCIUM SULPHATE HEMI-HYDRATE FOR THE MANUFACTURE OF MOULDS | Börgardts-Sachsenstein GmbH (DE) | 1987-12-09 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| US-4377577-A | Use of psychoactive drugs in uterus to prevent pregnancy | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1983-03-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | MEN1, ABCB1, ABCC1 | DRD2 4691/4885DRD3 4667/4885HTR2A 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.